Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 7:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 2,730 matching trials from the live ClinicalTrials.gov search.
Conditions
Gastric Carcinoma
Interventions
Tesetaxel, Placebo, Capecitabine
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumor
Interventions
enzastaurin, irinotecan, cetuximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Casa Grande, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
Conditions
Cancer, Hepatocellular
Interventions
nivolumab, ipilimumab, TACE
Drug · Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Coronado, California • Washington D.C., District of Columbia • Louisville, Kentucky + 1 more
Conditions
Pancreatic Cancer
Interventions
Capecitabine (Xeloda), Gemcitabine
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
18
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more
Conditions
Adenocarcinoma
Interventions
Immunotherapeutic Agents, Ablation
Drug · Device
Lead sponsor
Gary Onik MD
Individual
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Esophageal Cancer
Interventions
cisplatin, paclitaxel, surgical procedure, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
New York, New York
Conditions
Hepatocellular Carcinoma
Interventions
SOM230
Biological
Lead sponsor
Lynn Feun
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Miami, Florida
Conditions
Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasm
Interventions
99mTc-Macro Albumin Aggregate
Drug
Lead sponsor
Sirtex Medical
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Spokane, Washington
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Interventions
LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Duarte, California • Santa Monica, California • Denver, Colorado + 18 more
Conditions
Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Interventions
ZW251
Drug
Lead sponsor
Zymeworks BC Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
San Francisco, California • Santa Monica, California • Louisville, Kentucky + 5 more
Conditions
KRAS Altered Advanced or Metastatic Solid Tumors
Interventions
AMG 410, Pembrolizumab, Panitumumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Atlanta, Georgia + 7 more
Active, not recruiting Early Phase 1 Interventional

SBRT + Atezolizumab + Bevacizumab in Resectable HCC

NCT04857684
Conditions
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, Stereotactic Beam Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Ipilimumab, Nivolumab
Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Birmingham, Alabama • Miami, Florida • Rochester, Minnesota + 2 more
Conditions
Ovarian Cancer, Non Small Cell Lung Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Cancer of Head and Neck
Interventions
LY2523355, pegfilgrastim
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Jonesboro, Arkansas • Jacksonville, Florida • Macon, Georgia + 15 more
Completed Not applicable Interventional Results available

An Intraoperative Guidance Platform for Radio Frequency Ablation

NCT04152343
Conditions
Hepatocellular Carcinoma
Interventions
RFA Physics Library -- a Planning and Guidance Platform (PGP)
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
E7 TCR-T cells, Aldesleukin
Biological · Drug
Lead sponsor
Christian Hinrichs
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Conditions
Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
Interventions
Bosentan, Gemcitabine, Nab-paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Pancreas Cancer
Interventions
Bethanechol, Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Susan E. Bates
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Hepatocellular Carcinoma, Pancreas Cancer, Biliary Tract Neoplasms
Interventions
Actigraphy, Online Mindfulness Meditation, Smartphone Application-based Intervention, Survey Administration
Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Duarte, California
Conditions
Hepatocellular Carcinoma
Interventions
Sorafenib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Tucson, Arizona • Fort Myers, Florida • St. Petersburg, Florida + 4 more
Conditions
Advanced Solid Tumors
Interventions
INCB099280, adagrasib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Greeley, Colorado • Detroit, Michigan + 2 more
Conditions
Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions
Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas